Johnson & Johnson Just Got a Big FDA Win

Healthcare giant Johnson & Johnson (JNJ -1.15%) racked up another win this week from the U.S. Food and Drug Administration.

The regulator approved JNJ’s drug Imaavy to treat patients 12 and older who have a rare life-threatening condition called warm autoimmune hemolytic anemia (wAIHA), in which autoantibodies attack red blood cells, leading to severe anemia and fatigue. Between one and three new people per 100,000 are affected by wAIHA each year, and about 1 in 8,000 people live with the condition, according to JNJ.

Image source: Getty Images.

It’s the second FDA win in as many months for JNJ. In July, the company won FDA approval for its dual-energy ablation catheter, which can deliver radiofrequency and pulsed field energy to treat atrial fibrillation, a common heart rhythm disorder.

Today’s Change

(-1.15%) $-3.14

Current Price

$270.00

Key Data Points

Market Cap

$651BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Day’s Range

$269.55 – $272.90

52wk Range

$173.33 – $276.47

Volume

7.2M

Avg Vol

7.9M

Gross Margin

68.03%

Dividend Yield

2.44%